PEITHO Pulmonary Embolism Thrombolysis Study A prospective, randomized, double-blind, placebo-controlled, international, multicentre, parallel-group comparison trial evaluating the efficacy and safety of single i.v. bolus tenecteplase plus standard anticoagulation as compared with standard anticoagulation in normotensive patients with acute pulmonary embolism and with echocardiographic (or spiral CT) and laboratory evidence of right ventricular dysfunction.

Trial Profile

PEITHO Pulmonary Embolism Thrombolysis Study A prospective, randomized, double-blind, placebo-controlled, international, multicentre, parallel-group comparison trial evaluating the efficacy and safety of single i.v. bolus tenecteplase plus standard anticoagulation as compared with standard anticoagulation in normotensive patients with acute pulmonary embolism and with echocardiographic (or spiral CT) and laboratory evidence of right ventricular dysfunction.

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Tenecteplase (Primary) ; Fondaparinux sodium; Heparin; Low molecular weight heparins
  • Indications Pulmonary embolism
  • Focus Registrational; Therapeutic Use
  • Acronyms PEITHO
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 30 Mar 2017 This trial has been completed in Italy as per European Clinical Trials Database record.
    • 28 Mar 2017 Status changed from active, no longer recruiting to completed according to results published in the Journal of the American College of Cardiology.
    • 28 Mar 2017 Long-term outcome results published in the Journal of the American College of Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top